Objective To assess the response rates ( clinical and pathological ) with docetaxel and epirubicin combination chem-otherapy and its effect on outcome .Methods Locally advanced breast cancer ( LABC) patients who received NACT from January 2009 to December 2012 in this hospital were retrospectively analysed .Some information of the patients was collected including basic informa-tion, clinical stages and the situation of estrogen receptor and progesterone receptor .The regimens used for NACT consisted of six cycles of DEC (docetaxel 75 mg/m2, epirubicin 75 mg/m2, cyclophosphamide 500 mg/m2 on day 1, 3 weekly) and a sequential regimen (4 cy-cles of FEC, 5-flurouracil 600 mg/m2 , epirubicin 75 mg/m2 , cyclophosphamide 600 mg/m2 followed by 4 cycles of docetaxel 85 mg/m2 ) .Clinical response and pathological response rates , time of relapse and 3 year survival rate were assessed .Results The median age was 46 years.Ninety-six patrents (80%) had T4 disease and 90%had clinically palpable lymph nodes at diagnosis .The median size of primary tumor at presentation was 5.9 cm.Hormone receptor positivity was seen in 55%of patients and HER2eu positivity in 25%. Triple negative breast cancers constituted of 25%of the patients.Totally 100 cases showed clinical response , accounting for 83%;15 ca-ses showed clinical stability;5 cased showed clinical progress .18 cases showed pathological response .There were no significant differ-ences between the two groups in the above data .The median duration of follow-up was 22 months.The median time to relapse was 20 months;3 year relapse free and overall survival rates were 50%and 70%, respectively .The differences between the two groups was not statically significant .Conclusions LABC patients have good outcome after neoadjuvant chemotherapy .Sequential chemotherapy is well tolerated than concurrent docetaxel and epirubicin chemotherapy with a similar PCR ( pathological complete response ) .%目的：评估多西他赛与表柔比星的化学药物治疗（化疗）组合对局部晚期乳腺癌（ locally advanced breast cancer ， LABC）的预后影响。方法回顾分析沈阳军区总医院2009-01至2012-12接受新辅助化疗（ neoadjuvant chemotherapy ，NACT）的120例LABC患者，收集入选患者的基本信息、临床分期、雌激素和孕激素受体状态等指标。联合用药方案（联合组）为6个DEC周期（每周第1、3天联合使用多西他赛75 mg/m2，表柔比星75 mg/m2，环磷酰胺500 mg/m2）；序贯用药方案（序贯组）为4个FEC周期（5-氟尿嘧啶600 mg/m2，表柔比星75 mg/m2，环磷酰胺600 mg/m2），以及4个多西他赛（85 mg/m2）周期。统计两组患者的临床和病理缓解情况、复发时间及3年生存率。结果患者平均年龄46岁。 T4期肿瘤患者96例（80％），其中90％可触及淋巴结。原发肿瘤平均大小为5．9 cm。激素受体阳性患者占55％，HER2阳性患者占25％，三阴乳腺癌患者占25％。两组中临床完全或部分缓解的有100例，占83％，疾病稳定15例，疾病进展5例；病理缓解18例，占15％。两种给药方式所获得的临床及病理缓解率无统计学差异。随访期平均为22个月，平均复发时间20个月，3年无复发病例占50％，3年生存率70％，两组间无明显差异。联合组有5例患者死于毒性反应，15％患者有伴发热的中性粒细胞减少症。结论 NACT可以改善LABC患者预后，序贯化疗方案患者耐受性较好。
展开▼
